Global Oncolytic Virus Immunotherapy Market Opportunity and Clinical Trials Insight 2030

Buy USD 20,000 Worth Of Reports (Single User/Multi User License) In USD 8000 Only

Global Oncolytic Virus Immunotherapy Market Opportunity and Clinical Trials Insight 2030 Report Highlights:

Global Oncolytic Virus Immunotherapy Therapy Market Opportunity: > USD 1.50 Billion By 2030
Oncolytic Viruses Immunotherapies Clinical Trials By Company, Indication and Phase
Comprehensive Insight On Oncolytic Virus Immunotherapies In Clinical Trials: > 180 Therapies
FDA and EMA Designations: Breakthrough Therapy, Fast Track, Orphan, PRIME
Patent Analysis Therapies in Clinical Trials
IMLYGIC, Oncorine, Delytact: Availability, Dosage and Price Analysis
Platforms Used For Developing Advanced Oncolytic Virus Immunotherapy

Cancer endures to be a relentless adversary, challenging both patients and the medical community across the world. The quest of innovative and targeted therapies to battle against this multifaceted disease has led to remarkable advancements in the field of cancer therapy. Amidst the many emerging strategies, oncolytic virus immunotherapy has captured the attention of researchers and clinicians as a promising avenue for cancer treatment in the recent years. The realm of oncolytic virus immunotherapy harnesses the natural characteristics of viruses to selectively target and destroy cancer cells, offering a unique and precision oriented approach to treatment. As this therapeutic paradigm progresses from the realm of scientific discovery to commercial viability, it brings forth a multitudinous of opportunities and challenges that shape the dynamics of the commercial market.

Hitherto, 3 oncolytic virus immunotherapies, namely Oncorine (H101), Imlygic (Talimogene laherparepvec), and teserpaturev (G47∆; Delytact), have been approved over the preceding decennium for the treatment of different types of cancer like head and neck cancer, melanoma and malignant glioma. However, it is expected that the domain will observe many more approvals in the upcoming years because of that fact that a handful of advanced oncolytic virus immunotherapies such as Oncos 102, CAN-2409, Pelareorep, CG070, VG161 have received designations like Fast Track, Orphan Drug, PRIME from regulatory agencies, FDA and EMA.

In the clinical field, oncolytic viruses are at the forefront of innovative research and therapeutic development. These viruses, carefully engineered or selected for their innate oncolytic properties, are designed to infiltrate cancer cells, replicate within them, and induce their destruction while simultaneously stimulating an immune response. Moreover, as the sphere of oncolytic virus immunotherapy surpasses the confines of laboratories and clinical trials, its journey into the commercial arena is characterized by an involvement of pharma companies that will aid to shape its trajectory in the global cancer treatment landscape.

The triumph of other immunotherapies, such as checkpoint inhibitors and CAR-T cell therapies, has generated considerable interest in harnessing the immune system to fight cancer. Oncolytic virus immunotherapy complements these approaches by utilizing viruses to stimulate an immune response against cancer cells. The positive outcomes from these immunotherapies have fueled interest in leveraging the immune system to combat cancer, leading to increased exploration of oncolytic virus immunotherapy as a complementary and synergistic approach.

On that account, multiple studies are ongoing in the clinical pipeline which comprise the combinations of oncolytic viruses with different types of antibodies targeting immune checkpoint receptors such as delolimogene mupadenorepvec with atezolizumab, OH2 injection, with or without irinotecan or HX008, ADV/HSV-tk with Pembrolizumab, for the treatment of patients suffering from wide array of cancer subtypes such as pancreatic cancer, Gastrointestinal Cancer, breast cancer etc.

Competition from the involvement of multitudinous pharmaceutical companies such as Merck, Bristol-Myers Squibb, Astellas Pharma, Roche, Lokon Pharma, NRG oncology, CG oncology, Genemedicine, Binhui Biopharmaceutical Barinthus Biotherapeutics, TILT Biotherapeutics, Genelux Corporation, Replimune, and Candel Therapeutics have created wave in the commercial market of oncolytic virus immunotherapy. As a result, the clinical development landscape will observed several pharmaceuticals companies commencing research in order to understand the oncolytic virus mode of actions which will aid to develop advanced and innovative oncolytic virus immunotherapy with least possible side effects.

It is projected that the market of oncolytic virus immunotherapy is poised to expand and multiply further in the forthcoming years due to the augmenting government regulatory approvals in conjugation with snow balling investments, collaborations and partnerships in the pharmaceutical sector. As of May 2024, the oncolytic virus is crowded by usage of different types of oncolytic virus like herpes simplex type-1 virus (HSV-1) or adenoviruses with or without chemotherapy, monoclonal antibodies directing against PD-1 and PD-L1 receptors, therapeutic peptide vaccines or nanoparticles in order to optimize delivery and performance for cancer treatments.

Currently, the US remains the market leader of the market as evident from rising collaborations, advancement and government bestow. The synergy between these clinical and commercial aspects propels the field forward, offering new expectation to cancer patients and shaping the future of cancer treatment. Continuous research, innovation, and collaboration are essential to sustaining this growth and realizing the full potential of oncolytic virus immunotherapy. As research further delves deeper into understanding the complexities of this innovative approach, there is optimism that oncolytic viruses will emerge as a valuable addition for cancer treatments, offering new avenues for improved outcomes and enhanced quality of life for patients.

oncolytic virus immunotherapy Oncolytic Virotherapy oncolytic virus therapy oncolytic virus treat cancer treatment oncolytic virus examples oncolytic virus delivery oncolytic virus replication selectivity oncolytic virus cost oncolytic virus approved oncolytic virus research oncolytic virus study oncolytic virus clinical trials oncolytic virus gene therapy oncolytic virus success rate oncolytic virus indications oncolytic virus diseases oncolytic virus therapy market oncolytic virus melanoma oncolytic virus benefits oncolytic virus clinical landscape oncolytic virus working oncolytic virus development advances oncolytic virus review virus therapy virology oncolytic virus novel approach oncolytic virus approved oncolytic virus need oncolytic virus glioma brain tumor oncolytic virus pancreatic cancer oncolytic virus ovarian cancer oncolytic virus lymphoma oncolytic virus lung cancer SCLC oncolytic virus breast cancer tnbc oncolytic virus prostate cancer oncolytic virus hepatocellular cancer oncolytic virus platform technology oncolytic virus companies oncolytic virus combinations oncolytic virus nanoparticles oncolytic virus chemotherapy oncolytic virus hemotherapeutic drugs oncolytic virus peptides oncolytic virus targeted therapies oncolytic virus future opportunity avenueoncolytic virus regulatory designations oncolytic virus fda oncolytic virus ema oncolytic virus safety efficacy oncolytic virus progress challenges oncolytic virus market oncolytic virus sales oncolytic virus Imlygic oncolytic virus Amgen oncolytic virus alimogene laherparepvec oncolytic virus t-vec oncolytic virus Oncorine H101 oncolytic virus China NMPA oncolytic virus Shenzhen SiBiono GeneTech oncolytic virus Delytact Oncolytic virus third generation oncolytic virus teserpaturev oncolytic virus G47 oncolytic virus HSV-1 oncolytic virus Japan MHLW oncolytic virus latest breakthrough oncolytic virus news oncolytic virus ollaborations oncolytic virus patents oncolytic virus Immune System stimulation oncolytic virus Checkpoint Combo oncolytic virus tumor warm up hot engineered virus recombinant virus oncolytic virus early promising result oncolytic virus mechanism oncolytic virus Kalivir oncolytic virus calidi oncolytic virus renovo oncolytic virus ValoTx Valo Therapeutics oncolytic virus transgene oncolytic virus imugene oncolytic virus epicentrx oncolytic virus genelux oncolytic virus new era Paradigm Oncolytic mmunoViroTherapy engineering strategies enhance oncolytic virus oncolytic virus genetically genetic

Introduction to Oncolytic Virus Immunotherapy

1.1 Overview

1.2 Need of Oncolytic Virus Immunotherapy

Globally Approved Oncolytic Virus Immunotherapies

2.1 Commercially Approved Therapies

2.2 FDA and EMA Designations: Breakthrough Therapy, Fast Track, Orphan, PRIME

Global Oncolytic Virus Immunotherapies Clinical Trials Overview

3.1 By Phase

3.2 By Country

3.3 By Company

3.4 By Indication

3.5 By Priority Status

3.6 Patient Segment

Global Oncolytic Virus Immunotherapy Market Trend and Developments

4.1 Current Market Outline

4.2 Future Market Forecast

Global Oncolytic Virus Immunotherapy Market Trends By Region

5.1 South Korea

5.2 Japan

5.3 US

5.4 Europe

5.5 UK

5.6 China

5.7 Australia

Global Oncolytic Virus Immunotherapy Market Trends By Indications

6.1 Melanoma

6.2 Head and Neck Cancer

6.3 Glioma

6.4 Pancreatic Cancer

6.5 Ovarian Cancer

6.6 Lymphoma

6.7 Lung Cancer

6.8 Breast Cancer

6.9 Prostate Cancer

6.10 Hepatocellular carcinoma

Global Oncolytic Viruses Immunotherapies Clinical Trials By Company, Indication and Phase

7.1 Research

7.2 Preclinical

7.3 Phase-I

7.4 Phase-I/II

7.5 Phase-II

7.6 Phase-III

7.7 Registered

Marketed Oncolytic Viruses Immunotherapies Clinical Insight

Global Oncolytic Virus Immunotherapy - Availability, Dosage and Price Analysis

9.1 Imlygic

9.1.1 Overview and Patent Insights

9.1.2 Pricing and Dosage

9.2 Oncorine (H101)

9.2.1 Overview

9.2.2 Pricing and Dosage

9.3 Delytact

9.3.1 Overview

9.3.2 Pricing and Dosage

Platforms used for Developing Advanced Oncolytic Virus Immunotherapy

10.1 KaliVir VET Backbone Technology

10.2 Calidi’s Platform Technology

10.3 RenovoRx TAMP Platform

10.4 ValoTx PeptiCRAd

10.5 ValoTx PeptiVAX / PeptiENV / PeptiBAC

10.6 Transgene’s Invir.IO Platform

10.7 Transgene’s myvac Platform

10.8 Imugene’s CF33 Technology

10.9 EpicentRx AdAPT Platform

10.10 Genelux’s Choice Discovery Platform

Oncolytic Virus Immunotherapy Combinations with Other Therapeutic Agents

11.1 Oncolytic Virus Immunotherapy with Nano materials

11.2 Oncolytic Virus Immunotherapy with Chemotherapeutic Drugs

11.3 Oncolytic Virus Immunotherapy with Peptides

11.4 Oncolytic Virus Immunotherapy with Targeted Immunotherapies

Global Oncolytic Virus Immunotherapy Market Dynamics

12.1 Market Drivers

12.2 Market Challenges

Competitive Landscape

13.1 AdCure Bio

13.2 Beijing SyngenTech

13.3 BioVex Inc. (Amgen)

13.4 Calidi Biotherapeutics

13.5 Genelux Corporation

13.6 Immvira Pharma

13.7 Jennerex Biotherapeutics

13.8 KaliVir

13.9 Lokon Pharma

13.10 Oncolys BioPharma

13.11 PsiOxus Therapeutics (Akamis Bio)

13.12 Seneca Therapeutics

13.13 Shanghai Sunway Biotech

13.14 Takara Bio

13.15 TILT Biotherapeutics

13.16 Transgene

13.17 Virogin Biotechaa

Figure 1-1: Demonstration of Categorization of Oncolytic Viruses

Figure 1-2: Illustration of Major Events in Clinical Virotherapy

Figure 1-3: Comparison of Conventional Therapies v/s Oncolytic Virus Immunotherapy

Figure 1-4: Oncolytic Virus Immunotherapy - Advantages

Figure 3-1: Global – Oncolytic Virus Immunotherapies Clinical Trials By Phase (Numbers), 2024 -2030

Figure 3-2: Global – Oncolytic Virus Immunotherapies Clinical Trials By Country (Numbers), 2024 - 2030

Figure 3-3: Global – Oncolytic Virus Immunotherapies Clinical Trials By Company (Numbers), 2024 - 2030

Figure 3-4: Global – Oncolytic Virus Immunotherapies Clinical Trials By Indication (Numbers), 2024 - 2030

Figure 3-5: Global – Oncolytic Virus Immunotherapies Clinical Trials By Priority Status (Numbers), 2024 - 2030

Figure 3-6: Global – Oncolytic Virus Immunotherapies Clinical Trials By Patient Segment (Numbers), 2024 -2030

Figure 4-1: Global - Oncolytic Virus Immunotherapy Market Opportunity (US$ Million), 2023 -2030

Figure 4-2: Approved Oncolytic Virus Immunotherapy

Figure 4-3: Global Oncolytic Virus Immunotherapy Market - Key Players

Figure 4-4: Aspects Determining the Future of Oncolytic Virus Therapy Market

Figure 5-1: Barinthus Biotherapeutics - ChAdOx1-HBV and MVA-HBV Clinical Trials

Figure 5-2: GeneMedicine - Oncolytic Virus Pipeline

Figure 5-3: TBI-1401(HF10) Phase I Study – Initiation and Completion Year

Figure 5-4: Astellas Pharma - ASP1012

Figure 5-5: ASP1012 and Pembrolizumab Phase I Study – Initiation and Completion Year

Figure 5-6: CF33-hNIS-antiPDL Phase I Study – Initiation and Completion Year

Figure 5-7: Cretostimogene Grenadenorepvec Phase III Study – Initiation and Completion Year

Figure 5-8: Cretostimogene Grenadenorepvec FDA Designations to treat unresponsive Non-Muscle Invasive Bladder Cancer (NMIBC)

Figure 5-9: AdAPT-001 Phase I Study – Initiation and Completion Year

Figure 5-10: Pelareorep with INCMGA00012 Phase II Study – Initiation and Completion Year

Figure 5-11: Oncolytic Virus Immunotherapy Market Trend in the US

Figure 5-12: Aspects Influencing Oncolytic Virus Market in Europe

Figure 5-13: TILT-123 with Pembrolizumab Phase I Study – Initiation and Completion Year

Figure 5-14: BT-001 and Pembrolizumab Phase I Study – Initiation and Completion Year

Figure 5-15: Transgene - Oncolytic Virus Candidates

Figure 5-16: 21325-2-02 Phase IV Study – Initiation and Completion Year

Figure 5-17: OH2 - Combinations with Other Therapeutic Agents

Figure 5-18: VAXINIA – FDA Fast Track Designation

Figure 6-1: MQ710 and Pembrolizumab Phase I Study – Initiation and Completion Year

Figure 6-2: Combination of GALV-GP-R protein with PD1 antibody to Treat Melanoma

Figure 6-3: Replimune – Oncolytic Virus Candidates

Figure 6-4: Oncorine - Approved Oncolytic Virus Immunotherapy for Head and Neck Cancer

Figure 6-5: YSCH-01 Phase I Study – Initiation and Completion Year

Figure 6-6: Head and Neck Cancer - Clinical Pipeline of Oncolytic Viruses

Figure 6-7: Calidi Biotherapeutics - NSC.CRAd-S-pk7 for Glioblastoma

Figure 6-8: CRAd-S-pk7 Phase I Study – Initiation and Completion Year

Figure 6-9: CAN-3110 Phase I Study – Initiation and Completion Year

Figure 6-10: Pancreatic Cancer - Influencing Factors in Oncolytic Virus Immunotherapy Market

Figure 6-11: STI-1386 Phase I Study – Initiation and Completion Year

Figure 6-12: TBI-1401 (HF10) Phase I Study – Initiation and Completion Year

Figure 6-13: RenovoRx and Imugene - Collaboration

Figure 6-14: TILT-123 – Mode of Action

Figure 6-15: TILT-T563 Phase I Study – Initiation and Completion Year

Figure 6-16: Combinations of Oncolytic Virus with Other Therapies

Figure 6-17: Comparison of Olvi-Vec with Chemotherapy

Figure 6-18: RT-01 Phase I Study – Initiation and Completion Year

Figure 6-19: Advantages of Oncolytic Virus Immunotherapy to Treat Lymphoma

Figure 6-20: Lung Cancer - Commercial Market Landscape of Oncolytic Virus Immunotherapy

Figure 6-21: Pro2020000268 Phase II Study – Initiation and Completion Year

Figure 6-22: Combination of Radio Chemotherapeutic Drug with Oncolytic Virus

Figure 6-23: Prostate Cancer - Benefits of Oncology Virus Immunotherapy

Figure 6-24: HB-302/HB-301 Phase I/II Study – Initiation and Completion Year

Figure 6-25: CAN-2409 Phase III Study – Initiation and Completion Year

Figure 6-26: Reasons for Candel Therapeutics Decided to Reduce Staff

Figure 6-27: Pexavec – Mode of Action

Figure 6-28: OPTIONS-04 Phase III Study – Initiation and Completion Year

Figure 6-29: Replimune RP3 Oncolytic Virus Immunotherapy for Hepatocellular Carcinoma Treatment

Figure 9 -1: US – Cost of Supply of Imlygic 1 mpfu/mL and 100 mpfu/mL (US$), May’2024

Figure 9 -2: Imlygic – Dose for Initial Treatment Cycle and Subsequent Treatment Cycle (Million PFU/ml), September’2020

Figure 9 -3: Imlygic – Duration of Initial and Subsequent Treatment Cycle (weeks), September’2020

Figure 9 -4: Imlygic – Average Price of Initial Treatment Cycle and Each Subsequent Treatment Cycle (US$), September’2022

Figure 9 -5: Imlygic – Maximum Volume Administered by Size of Lesion (ml), September’2020

Figure 10-1: KaliVir Immunotherapeutics - VET Backbone Technology

Figure 10-2: Calidi Biotherapeutics Platform

Figure 10-3: ValoTx - PeptiCRAd

Figure 10-4: ValoTx - PeptiVAX / PeptiENV / PeptiBAC

Figure 10-5: Transgene - myvac

Figure 10-6: Genelux - Choice Discovery platform

Figure 11-1: Combination of Oncolytic Virus with Other Therapies

Figure 11-2: Combination of Oncolytic Virus Immunotherapy with Nano materials

Figure 11-3: Oncolytic Virus Immunotherapy and Nano materials – Mode of Action

Figure 11-4: Combination of Oncolytic Virus Immunotherapy with Peptides

Figure 12-1: Global Oncolytic Virus Immunotherapy - Market Drivers

Figure 12-2: Global Oncolytic Virus Immunotherapy - Market Challenges

Table 2-1: Approved Oncolytic Virus Immunotherapies

Table 5-1: US – Ongoing Clinical Trials for Oncolytic Virus Immunotherapy

Table 5-2: Europe – Ongoing Clinical Trials for Oncolytic Virus Immunotherapy

Table 6-1: Melanoma – Ongoing Clinical Trials for Oncolytic Virus Immunotherapy

Table 6-2: Head and Neck Cancer – Ongoing Clinical Trials for Oncolytic Virus Immunotherapy

Table 6-3: Glioma – Ongoing Clinical Trials for Oncolytic Virus Immunotherapy

Table 6-4: Pancreatic Cancer – Ongoing Clinical Trials for Oncolytic Virus Immunotherapy

Table 6-5: Ovarian Cancer – Ongoing Clinical Trials for Oncolytic Virus Immunotherapy

Table 6-6: Lung Cancer – Ongoing Clinical Trials for Oncolytic Virus Immunotherapy

Table 6-7: Breast Cancer – Ongoing Clinical Trials for Oncolytic Virus Immunotherapy

Table 9-1: Imlygic - Recommended Dose and Schedule

Report Title:

Name:

Email address:

Job title:

Organisation:

Contact number:

Country:

Payment Request

Report Title:

Name:

Email address:

Job title:

Organisation:

Contact number:

Country:

Accept Terms & Conditions And Privacy Policy

Global Oncolytic Virus Immunotherapy Market Opportunity and Clinical Trials Insight 2030

Buy USD 20,000 Worth Of Reports (Single User/Multi User License) In USD 8000 Only

Need custom market research solution? We can help you with that too.

About us

Quick links

Contact us

Stay Connected